Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T M Mulders

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Clinical Pharmacokinetics|October 6, 2000
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ringC J Timmer, T M Mulders
Fertility and Sterility|May 4, 2001
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibitionT M Mulders, T O Dieben
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1990
Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor markerT M Mulders, P F Bruning, J M Bonfrer
Human Reproduction (Oxford, England)|March 3, 2001
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiolF J Roumen, D Apter, T M Mulders, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 1999
Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolismF C Wu, R Balasubramanian, T M Mulders, et al.
Contraception|September 23, 1998
Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteersT M Mulders, C P Mink, I W Bobbink, et al.
Clinical Pharmacology and Therapeutics|January 1, 1993
Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy volunteersT M Mulders, V Venizelos, R Schoemaker, et al.
Biochemical Pharmacology|November 17, 1993
Stereoselectivity of human liver and intestinal cytosolic fractions as well as purified human glutathione S-transferase isoenzymes towards 2-bromoisovalerylurea enantiomersT M Mulders, B van Ommen, P J van Bladeren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancersT M Mulders, Keizer, J Ouwerkerk, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokineticsP A Soons, T M Mulders, E Uchida, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Clinical Pharmacokinetics|October 6, 2000
Pharmacokinetics of etonogestrel and ethinylestradiol released from a combined contraceptive vaginal ringC J Timmer, T M Mulders
Fertility and Sterility|May 4, 2001
Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibitionT M Mulders, T O Dieben
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1990
Prostate-specific antigen (PSA). A tissue-specific and sensitive tumor markerT M Mulders, P F Bruning, J M Bonfrer
Human Reproduction (Oxford, England)|March 3, 2001
Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiolF J Roumen, D Apter, T M Mulders, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 1999
Oral progestogen combined with testosterone as a potential male contraceptive: additive effects between desogestrel and testosterone enanthate in suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolismF C Wu, R Balasubramanian, T M Mulders, et al.
Contraception|September 23, 1998
Safety, tolerability, and pharmacokinetics of a novel, selective antiprogestagen (Org 31710) in healthy male volunteersT M Mulders, C P Mink, I W Bobbink, et al.
Clinical Pharmacology and Therapeutics|January 1, 1993
Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R)- and (S)-2-bromoisovalerylurea in healthy volunteersT M Mulders, V Venizelos, R Schoemaker, et al.
Biochemical Pharmacology|November 17, 1993
Stereoselectivity of human liver and intestinal cytosolic fractions as well as purified human glutathione S-transferase isoenzymes towards 2-bromoisovalerylurea enantiomersT M Mulders, B van Ommen, P J van Bladeren, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 1, 1995
Effect of ifosfamide treatment on glutathione and glutathione conjugation activity in patients with advanced cancersT M Mulders, Keizer, J Ouwerkerk, et al.
European Journal of Clinical Pharmacology|January 1, 1993
Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlation with nifedipine pharmacokineticsP A Soons, T M Mulders, E Uchida, et al.
Pageof 2